{
    "code": "52027145",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027145",
    "time": "2023-08-03 19:36:02",
    "許可證字號": "衛部藥輸字第027145號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/06\/08",
    "發證\/登錄日期": "106\/06\/08",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202714507",
    "中文品名": "百無凝膜衣錠60毫克",
    "英文品名": "BRILINTA Film-coated Tablets 60 mg",
    "適應症": "Brilinta 與Aspirin併用，可減少急性冠心症 (ACS) 病人或有心肌梗塞 (MI) 病史合併有高風險發生動脈血栓事件病人之栓塞性心血管 (CV) 事件的發生率。\r\n對於ACS病人的治療，與Clopidogrel 相比，Brilinta 可以降低心血管死亡、\r\n心肌梗塞發生率，於中風事件上，兩者並無差異；對於接受經皮冠狀動脈介入治療者，Brilinta 亦可減少支架栓塞的發生。",
    "劑型": "116膜衣錠",
    "包裝": "4-1000錠PVC\/PVDC鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "新療效(新適應症)",
    "監視期限": "111\/06\/08",
    "主成分略述": "TICAGRELOR",
    "限制項目": "02輸　入",
    "申請商名稱": "臺灣阿斯特捷利康股份有限公司",
    "申請商地址": "台北市大安區敦化南路二段207號21樓",
    "主製造廠": [
        {
            "製造廠名稱": "ASTRAZENECA AB",
            "製造廠廠址": "SE-151 85 SODERTALJE SWEDEN",
            "製造廠公司地址": "",
            "製造廠國別": "SWEDEN",
            "製程": ""
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "2012600300",
            "成分名稱": "TICAGRELOR",
            "含量描述": "",
            "含量": "60.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "2. Brilinta 60 90mg中文仿單July2021-110-07-27.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027145&Seq=003&Type=9"
        },
        {
            "title": "Brilinta 60mg-鋁箔-201904上傳-108-04-12(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027145&Seq=008&Type=8"
        },
        {
            "title": "Brilinta 60mg-外盒-201904上傳-108-04-12(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027145&Seq=007&Type=8"
        },
        {
            "title": "Brilinta 60mg-鋁箔-201904上傳-108-04-12(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027145&Seq=004&Type=8"
        },
        {
            "title": "Brilinta 60mg-外盒-201904上傳-108-04-12(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027145&Seq=003&Type=8"
        },
        {
            "title": "027145-Brilinta 60mg- blister-20170724-106-07-24(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027145&Seq=002&Type=8"
        },
        {
            "title": "52027145-106-06-26.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027145&Seq=001&Type=8"
        }
    ]
}